Sandu Pharma.

Which are the latest news on Sandu Pharma.?

Why is Sandu Pharmaceuticals Ltd falling/rising?

As of 14-Jun, Sandu Pharmaceuticals Ltd's stock price is Rs 41.61, down 3.1%, underperforming its sector. The stock has shown a troubling trend with a significant decline over the past year and decreasing investor participation.

As of 14-Jun, Sandu Pharmaceuticals Ltd's stock price is falling, currently at Rs 41.61, which reflects a decrease of Rs 1.33 or 3.1%. This decline is evident in today's performance, where the stock underperformed its sector by 5.08%. Additionally, the stock reached an intraday low of Rs 40, marking a significant drop of 6.85% during the day.<BR><BR>The stock's recent performance over various periods also indicates a troubling trend. Over the past week, it has decreased by 2.09%, while the benchmark Sensex has increased by 1.73%. Although there was a positive return of 8.19% over the past month, the year-to-date performance shows a gain of 11.17%, contrasting sharply with a 19.83% decline over the past year. Furthermore, the stock has underperformed significantly over longer periods, with a 27.55% drop over three years compared to a 20.41% gain in the Sensex.<BR><BR>Investor participation appears to be declining, as evidenced by a 32.78% drop in delivery volume on June 11 compared to the five-day average. This falling participation, combined with the stock trading below its recent highs and lower liquidity, suggests a lack of confidence among investors, contributing to the stock's downward movement.

How big is Sandu Pharma.?

As of 10th June, Sandu Pharmaceuticals Ltd has a market capitalization of 41.00 Cr, with recent net sales of 67.19 Cr and a net profit of 1.56 Cr. The company has shareholder's funds of 42.02 Cr and total assets of 55.72 Cr.

As of 10th June, Sandu Pharmaceuticals Ltd has a market capitalization of 41.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sandu Pharmaceuticals reported Net Sales of 67.19 Cr and a Net Profit of 1.56 Cr.<BR><BR>For the reporting period of March 2025, the company has Shareholder's Funds amounting to 42.02 Cr and Total Assets of 55.72 Cr.

Who are in the management team of Sandu Pharma.?

The management team of Sandu Pharma includes Umesh B Sandu (Managing Director), Pratika Mhambray (Company Secretary), and several Non-Executive Directors: Dilip R Salgaocar, Krishna B Deshpande, Madan Laxman Kapre, K Vinay Kumar, Shashank B Sandu, and Shubhada P Sandu. This team combines executive leadership with independent oversight.

The management team of Sandu Pharma includes the following individuals:<BR><BR>1. **Umesh B Sandu** - Managing Director<BR>2. **Pratika Mhambray** - Company Secretary & Compliance Officer<BR>3. **Dilip R Salgaocar** - Non-Executive & Independent Director<BR>4. **Krishna B Deshpande** - Non-Executive & Independent Director<BR>5. **Madan Laxman Kapre** - Non-Executive & Independent Director<BR>6. **K Vinay Kumar** - Non-Executive & Independent Director<BR>7. **Shashank B Sandu** - Non-Executive & Non-Independent Director<BR>8. **Shubhada P Sandu** - Non-Executive & Non-Independent Director<BR><BR>This team brings a mix of executive and independent oversight to the company.

Who are the peers of the Sandu Pharma.?

Sandu Pharma's peers include Veerhealth Care, Mangalam Drugs, Rajnish Wellness, Vista Pharma, Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, and Medi Caps. Most peers exhibit below-average management risk and growth, with Veerhealth Care showing the highest 1-year return at 39.82% and Mangalam Drugs the lowest at -65.43%.

Peers: The peers of Sandu Pharma are Veerhealth Care, Mangalam Drugs, Rajnish Wellness, Vista Pharma, Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, and Medi Caps.<BR><BR>Quality Snapshot: Below Average management risk is observed at all peers, including Veerhealth Care, Mangalam Drugs, Rajnish Wellness, Vista Pharma, Murae Organisor, Lasa Supergeneri, Roopa Industries, ANG Lifesciences, and Medi Caps. Average growth is found at Sandu Pharma and Rajnish Wellness, while Below Average growth is noted for Mangalam Drugs, Vista Pharma, Lasa Supergeneri, ANG Lifesciences, and Medi Caps, with Good growth at Murae Organisor and Excellent growth at Roopa Industries. Sandu Pharma and Medi Caps have a Good capital structure, while the rest have Below Average capital structure.<BR><BR>Return Snapshot: Veerhealth Care has the highest 1-year return at 39.82%, while Mangalam Drugs has the lowest at -65.43%, with Sandu Pharma's 1-year return at -21.83% being significantly lower than Veerhealth Care's but higher than Mangalam Drugs'. Additionally, several peers, including Murae Organisor, Lasa Supergeneri, and Medi Caps, have negative six-month returns.

What does Sandu Pharma. do?

Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic medicines, operating as a Micro Cap company since its establishment in 1985. As of March 2026, it reported net sales of 17 Cr and a market cap of INR 41 Cr.

Overview:<BR>Sandu Pharmaceuticals Ltd is engaged in the manufacturing and trading of Ayurvedic medicines and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Established in 1985, Sandu Pharmaceuticals Ltd has been involved in the Ayurvedic medicine sector since its inception. The company went public in September 1994, issuing 17.70 lac equity shares to finance a new project in Goa. The latest reported quarter for sales and profit is March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 17 Cr (Quarterly Results - Mar 2026)<BR>Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap: INR 41 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 25.00<BR>Industry P/E: 21<BR>Dividend Yield: 1.90%<BR>Debt Equity: -0.05<BR>Return on Equity: 3.71%<BR>Price to Book: 0.97<BR><BR>Contact Details:<BR>Address: Plot No 25/26/29 & 30, Pilerne Indl Estate Marra Bard Bardez Goa : 403511<BR>Website: http://www.sandu.in

Should I buy, sell or hold Sandu Pharmaceuticals Ltd?

When is the next results date for Sandu Pharmaceuticals Ltd?

The next results date for Sandu Pharmaceuticals Ltd is 05 May 2026.

The next results date for Sandu Pharmaceuticals Ltd is scheduled for 05 May 2026.

Is Sandu Pharma. overvalued or undervalued?

As of November 21, 2025, Sandu Pharma is considered undervalued with an attractive valuation grade, featuring a PE ratio of 24.77, an EV to EBITDA of 13.26, and a Price to Book Value of 0.92, significantly lower than its peers, despite a year-to-date stock decline of 30.14% compared to the Sensex's gain of 9.08%.

As of 21 November 2025, the valuation grade for Sandu Pharma has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 13.26, and a Price to Book Value of 0.92, which suggest that the stock is trading at a reasonable valuation compared to its earnings and asset base.<BR><BR>In comparison to its peers, Sandu Pharma's PE ratio is significantly lower than that of Elitecon International, which stands at 239.98, and MMTC, which has a PE of 133.45. This positions Sandu Pharma favorably within the pharmaceuticals and biotechnology sector, especially when considering its attractive valuation grade. Notably, the company's recent stock performance has lagged behind the Sensex, with a year-to-date decline of 30.14% compared to the Sensex's gain of 9.08%, further reinforcing the notion that it may be undervalued in the current market environment.

How has been the historical performance of Sandu Pharma.?

Sandu Pharma has shown stable financial performance, with net sales slightly decreasing from 67.28 Cr in Mar'24 to 67.19 Cr in Mar'25, while operating profit and profit after tax increased modestly. Total assets rose from 52.41 Cr to 55.72 Cr, indicating consistent asset management.

Answer:<BR>The historical performance of Sandu Pharma shows a relatively stable financial trajectory over the past few years.<BR><BR>Breakdown:<BR>Sandu Pharma's net sales have remained consistent, with a slight decrease from 67.28 Cr in Mar'24 to 67.19 Cr in Mar'25, following a gradual increase from 65.35 Cr in Mar'23 and 65.50 Cr in Mar'22. The total operating income mirrored this trend, reflecting the same figures as net sales. The total expenditure, excluding depreciation, decreased slightly from 64.99 Cr in Mar'24 to 64.43 Cr in Mar'25, contributing to an operating profit (PBDIT) increase from 2.71 Cr to 2.93 Cr during the same period. Profit before tax also saw a modest rise from 2.07 Cr in Mar'24 to 2.16 Cr in Mar'25, while profit after tax increased from 1.46 Cr to 1.55 Cr. The earnings per share (EPS) improved from 1.51 in Mar'24 to 1.6 in Mar'25, although it has decreased from 1.8 in Mar'22. On the balance sheet, total assets rose from 52.41 Cr in Mar'24 to 55.72 Cr in Mar'25, with total liabilities also increasing from 52.41 Cr to 55.72 Cr. The cash flow results indicate a stable cash position, with closing cash and cash equivalents remaining at 1.00 Cr for both Mar'25 and Mar'24. Overall, Sandu Pharma has demonstrated steady performance with slight fluctuations in profitability and consistent asset management.

Are Sandu Pharma. latest results good or bad?

Sandu Pharmaceuticals' latest results are unfavorable, with a 18.1% decline in net sales and a 41.07% drop in net profit for the quarter ending March 2025, leading to a 'Strong Sell' rating from MarketsMOJO due to serious financial concerns.

The latest results for Sandu Pharmaceuticals indicate a challenging financial performance. For the quarter ending March 2025, the company reported net sales of Rs 14.07 crore, which is a significant decline of 18.1% compared to the average net sales of Rs 17.18 crore over the previous four quarters. This figure represents the lowest net sales for Sandu Pharmaceuticals in the last five quarters.<BR><BR>Additionally, the company's consolidated net profit saw a sharp decrease of 41.07%, reflecting ongoing difficulties in maintaining profitability. The operating profit also experienced a decline of 54.55%. Given these results, MarketsMOJO has issued a 'Strong Sell' rating for the company, indicating serious concerns about its financial health and future prospects.<BR><BR>Overall, the financial results suggest that Sandu Pharmaceuticals is facing significant challenges, making the latest performance appear unfavorable.

What is the technical trend for Sandu Pharma.?

As of June 5, 2025, Sandu Pharma's technical trend is mildly bearish, with mixed signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, alongside bearish weekly RSI and daily moving averages.

As of 5 June 2025, the technical trend for Sandu Pharma has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The weekly RSI is bearish, while the monthly RSI shows no signal, suggesting weakness in momentum. Moving averages on the daily chart are mildly bearish, reinforcing the negative sentiment. Bollinger Bands indicate a mildly bullish stance on the weekly but bearish on the monthly, adding to the mixed outlook. The KST is mildly bullish weekly but bearish monthly, and Dow Theory shows a mildly bearish trend on the weekly with no trend on the monthly. Overall, the current stance is mildly bearish, with key indicators like the daily moving averages and the monthly MACD contributing to this view.

Who are the top shareholders of the Sandu Pharma.?

The top shareholders of Sandu Pharma are Umesh Bhaskar Sandu with 14.37%, and Sanmark Realty And Finance Private Limited with 5.63%. Individual investors collectively own 35.9% of the shares, with no institutional or mutual fund holdings.

The top shareholders of Sandu Pharma include Umesh Bhaskar Sandu, who holds the highest promoter stake at 14.37%. Additionally, Sanmark Realty And Finance Private Limited is the largest public shareholder with a holding of 5.63%. Individual investors collectively hold 35.9% of the shares. There are no institutional investors or mutual funds currently holding shares in the company.

Has Sandu Pharma. declared dividend?

Sandu Pharmaceuticals Ltd has declared an 8% dividend, amounting to ₹0.80 per share, with an ex-date of September 19, 2024. While recent total returns show declines over shorter periods, the company has experienced substantial gains over the longer term.

Sandu Pharmaceuticals Ltd has declared an 8% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 8%<BR>- Amount per share: ₹0.80<BR>- Ex-date: 19 Sep 2024<BR><BR>Dividend Yield: 1.55%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -12.48%, with a dividend return of 0%, resulting in a total return of -12.48%.<BR><BR>In the 1-year period, the price return was -16.07%, the dividend return was 1.34%, leading to a total return of -14.73%.<BR><BR>For the 2-year period, the price return was -11.88%, the dividend return was 2.55%, culminating in a total return of -9.33%.<BR><BR>During the 3-year period, the price return was -25.96%, with a dividend return of 3.55%, resulting in a total return of -22.41%.<BR><BR>In the 4-year period, the price return was 25.8%, the dividend return was 4.83%, producing a total return of 30.63%.<BR><BR>Over the 5-year period, the price return was 220.0%, with a dividend return of 14.52%, leading to a total return of 234.52%.<BR><BR>Overall, Sandu Pharmaceuticals Ltd has declared a dividend, but the total returns over various periods show a mixed performance, with significant declines in shorter periods and substantial gains over the longer term. The recent dividend declaration may provide some relief to investors amidst the fluctuating returns.